论文部分内容阅读
去铁敏(DFX)常规皮下输注疗法,是使常规输血的难治性贫血(如β-重型地中海贫血)患者大量排铁和预防因输铁过量而死亡的一种方法。一些研究证实,铁过量患者每天8～12小时内皮下输注 DFX1～4g,每天尿可排铁200mg。作者对34例输铁过量的患者用 DFX 皮下输注5～20个月.34例患者,其中31例β-重型地中海贫血,2例成铁细胞性贫血,1例纯红细胞发育不全。地中海贫血患者输血80～430单位,12小时内给患者皮下缓慢输注 DFX2～4g,每晚1次,每周6次,并每天口服维生素 C200mg,在 DFX 疗法5～20个月后重复进行铁蛋白测定和肝功能试验。结果 34例在开始 DFX 常规治疗后5个月,血清铁蛋白降至始值以下,并继续下降,行脾切除与否
Conventional subcutaneous iron infusion (DFX) subcutaneous infusion therapy is a method of massively draining iron from refractory anemia (such as β-thalassemia major) that is conventionally transfused and preventing death due to iron overload. Some studies have confirmed that patients with iron overload 8-12 hours a day subcutaneous infusion of DFX1 ~ 4g, urine per day of iron 200mg. In this study, 34 patients with iron overload were infused subcutaneously with DFX for 5 to 20 months. Of the 34 patients, 31 were β-thalassemia, 2 had iron-forming anemia, and 1 had pure red cell hypoplasia. Patients with thalassemia transfusion of 80 to 430 units within 12 hours to patients with subcutaneous slow infusion of DFX2 ~ 4g, 1 night, 6 times a week, and oral vitamin C 200mg, DFX therapy in 5 to 20 months after the repetition of iron Protein Assay and Liver Function Test. Results In 34 cases, 5 months after the start of routine DFX treatment, serum ferritin decreased below the initial value and continued to decline. Splenectomy was performed or not